Cancer and Tumor Review

ISSN: TBA (Online)

Journal Abbreviation: Cancer Tumor Rev

Publication Frequency: quarterly

Article Processing Charges (APC): Click here for more details

Publishing Model: Open Access

Journal no: 67P

About the Journal

Cancer and Tumor Review is an international Open Access journal that publishes articles related to all areas of cancers and tumors. The topics of interest include but not limited to diagnosis, therapy, imaging, prevention, quality of life, supportive care, education and awareness.

Recently Published Articles


Xinran Zhao
8 Views, 12 PDF Downloads

Objective: To perform PICC catheterization in 129 hospitalized patients with chemotherapy for infusion of
chemotherapy. The clinical response of patients with PICC after catheterization is to find out the causes of
complications and to give appropriate care. This is to investigate the causes and nursing strategies of common
complications after PICC catheterization in patients with chemotherapy. Methods: It gives the patient and his family
explain, sign PICC informed consent, evaluate and select the appropriate vein, assist the patient to take the supine
position, puncture side arm abduction 90 degrees, measure the puncture site to the right sternoclavicular joint The
length of the third intercostal (the length of the position to the end of the catheter) and the length of the arm of 10 cm
on the elbow, and record well. With sterile gloves with alcohol and povidone-iodine 3 times disinfection puncture
site skin up and down 15cm, replace sterile gloves, wear isolation clothing, shop large single, shop sterile towel
and hole towel, remove the PICC catheter and puncture sheath, and puncture, remove the puncture sheath sheath,
under the elbow joint 2cm at the puncture, see the blood after the needle and then a little to ensure that the needle
bevel completely into the blood vessels, loose tourniquet, withdrawal Needle tube, press the end of the tube to stop
bleeding, the pre-punched catheter along the puncture sheath tube forward tube, tube to 15cm when the patient with
the head toward the puncture side and close to the shoulder, tube to the required length, Will be introduced into the
guide wire from the catheter, then take the saline syringe back to the blood (to ensure that the catheter in the blood
vessels), then to joints, slow injection of saline and then heparin dilution positive pressure sealing tube. With a small
yarn block covered puncture points, transparent dressings and elastic bandage to stop bleeding. To help patients with
chest radiographs to determine the location of the infusion device and the catheter after the end of the connection
can be infusion. To the patients and their families to explain the tube and tube with the attention during the catheter
and catheter stay time to get with, to prevent the occurrence of complications, make a record. Results: In this group,
7 cases of puncture point bleeding, the incidence was 5.4%, 3 cases of puncture infection, the incidence of 2.3%, 3
cases of phlebitis, the incidence of 2.3%, 2 cases of catheter blockage, the incidence of 1.6% , 2 cases of catheter
prolapse, the incidence of 1.6%, 1 case of thrombosis, the incidence was 0.8%. Conclusion: The application of PICC
intravenous chemotherapy, catheter retention time is long, can be repeated, intermittent application. There is no need
to strictly restrict the patient's activities during the course of the tube, which has no serious effect on the work and
daily life of the patients. It provides a safe, convenient and effective intravenous treatment channel for the patients
with cancer, improving the quality of life and the satisfaction of the care.



Gang Yan
9 Views, 8 PDF Downloads

Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. It is also a high
incidence of malignancy in our country. It is difficult to be diagnosed early, and it is easy to relapse and metastasis
after operation. At present, liver cancer is still recognized as the preferred surgical treatment and the main treatment,
but because many patients with liver cancer diagnosis is in the late, lost the chance of surgical treatment and death
within 1 year after diagnosis, surgical resection rate of 30%, the overall 5-year survival rate is only 30% to 40%. For
patients with hepatocellular carcinoma, postoperative recurrence and metastasis are the main factors affecting the
therapeutic effect and prognosis, and there is still no effective treatment for patients with advanced hepatocellular
carcinoma who cannot be operated. Traditional chemotherapy, radiotherapy for poor efficacy of liver cancer, there
is still a lack of effective chemical prevention and treatment of target [1]. Therefore, this study is the mechanism
of compound A combined with compound B on human hepatoma HepG2 cells. In this study, MTT assay was
used to detect the effects of different concentrations of A and B on HepG2 cells and the combination of different
concentrations of A and B in the treatment of HepG2 cells. The results showed that different concentrations of A and B
alone treated HepG2 cells, the degree of inhibition of the performance of time-dose-dependent effect, and in A 6μmol
/ L combined B 100μmol / L synergistic effect is most significant. Flow cytometry showed that the apoptosis rate of
the combination group was more obvious. Western Blot assay showed that the expression of Bax and FADD increased
and the expression of anti-apoptotic protein Bcl-2 was decreased.



Mingzhu Yue
7 Views, 22 PDF Downloads

Purpose: (1) To investigate the expression of CaSR in papillary thyroid carcinoma, thyroid benign lesion and normal
thyroid cells by immunohistochemistry and to analyze the relationship between CaSR and papillary thyroid carcinoma.
(2) To study the difference of the expression of thyroid papillary carcinoma between calcification group and thyroid
papillary carcinoma without calcification and the difference of calcification between thyroid papillary carcinoma
and benign thyroid lesions and to analyze its significance. (3) To investigate the expression characteristics of CaSR
in blood stasis syndrome group and non-blood stasis syndrome group and to analyze the correlation between CaSR
and TCM blood gall blood stasis syndrome. Methods: Thirty patients (thyroid papillary carcinoma and 40 cases of
thyroid benign tumor) were treated with MaxvisionTM2 / HRP immunohistochemical two-step method to investigate
the effect of CaSR on thyroid papillary carcinoma, thyroid benign lesion and normal thyroid tissue. All data were
analyzed by SPSS 17.0 using nonparametric test, P <0.05 for the difference was statistically significant. Results:
The expression of CaSR in thyroid papillary carcinoma and the positive expression of CaSR in thyroid benign lesion
were statistically significant. (3) CaSR in thyroid papillary carcinoma was significantly higher than that in CaSR (P
<0.05) and the positive expression of CaSR in the calcification group of thyroid papillary carcinoma was higher than
that in benign thyroid calcification group, the difference was statistically significant. (3) The expression of CaSR in
thyroid papillary carcinoma was significantly higher than that in thyroid papillary carcinoma. There was a significant
difference in the positive expression of CaSR between blood stasis syndrome group and non - blood stasis syndrome
group (P <0.05). Conclusion: (1) CaSR in normal thyroid tissue in a small amount or no expression in papillary
thyroid carcinoma and thyroid benign lesions in the expression of thyroid papillary carcinoma in the high expression
of: (2) CaSR in the thyroid papillary carcinoma of the calcification group (P <0.05) .In conclusion, CaSR may play a
key role in the calcification of thyroid papillary carcinoma; (3) CaSR may play an important role in the calcification
of thyroid papillary carcinoma. The positive expression of blood stasis syndrome group was higher than that of nonblood
stasis syndrome group which indicated that CaSR might be correlated with Chinese medicine gall blood stasis



Guodong Cheng
9 Views, 17 PDF Downloads

Objective: To investigate the changes of cell cycle and the content of P53 protein in S180 cells by using the specific
fluorescent probe to identify the biological target to be measured according to the change of the fluorescence signal.
The results showed that Shikonin had good anti-tumor effect. Methods: Cell cycle changes and P53 protein content in
S180 cells were detected by flow cytometry. Results: With the increase of Shikonin dose, S180 cells G1 and S phase
content gradually increased, it can be inferred Shikonin action in cells, and the cells can be blocked in G1 and S phase.
With the increase of the dose of Shikonin, the expression of P53 protein increased. This suggests that Shikonin may
up-regulate P53 activity and induce apoptosis. Conclusion: From the experimental results, we can see that Shikonin
has a good antitumor effect in vivo.



Kaplan Mones
9 Views, 37 PDF Downloads

Most of the enzymes are proteins and there are a few macromolecules with biocatalytic activity such as RNA and
DNA. Ribozyme (Rz) is a class of biocatalytic RNA. The substrate is a ribozyme of the RNA molecule that catalyzes
the cleavage and splicing of the substrate RNA. Its role is characterized by low cutting efficiency and is easily
destroyed by RNase. The catalytic type includes RNA transnucleotide reaction, RNA restriction endonuclease reaction
(hydrolysis reaction) and polymerase activity reaction (link reaction). It may have amino acid esterase, amino acid
tRNA synthetase and peptide transfer. Activity of the enzyme indicates that the ribozyme plays an important role in the
process of translation and ribosome function. The ribozymes currently found include class I introns, class II introns,
RNaseP, hammerhead, hairpin and axular ribozyme (hepatitis D virus ribozyme). Recent studies have confirmed
that ribozymes are commonly found in nature and their secondary structures are composed of amino acid arms,
dihydropyrimidine rings, anti-cryptocycles, additional rings and TφC rings. Ribozyme is a catalyst that can be used
repeatedly. As compared with antisense RNA, ribozyme drugs use less dose, toxicity is small and the role of ribozyme
on the virus targeting sequence is specific hence rendering the virus more difficult to produce tolerance. The use of
ribozyme is to splice the highly specific treatment of the corresponding disease has long-term prospects. At present,
ribozyme technology is a promising application of gene therapy although in 20 years has been a huge development
but there are many problems are not resolved such as in vitro screening of high activity of ribozymes, (Hairpin
ribozyme), ax ribozyme (The ax of the ribozyme) research. The establishment of efficient expression system in vivo,
enhanced ribozyme in the cell cutting efficiency and to seek more effective carrier. The resolution of these problems,
the ribozyme in the clinical application of the time to further shorten. At present, although the anti-tumor and antiviral
activity of ribozyme is still in the experimental stage, it has revealed the dawn of hope. This article provides a brief
overview of the use of ribozymes in antitumor and antiviral therapy in recent years.

Read more

Indexing and Archiving

Cancer and Tumor Review (CTR) aims to be indexed by world-recognized databases, for example, PubMed, Scopus and Science Citation Index (SCI).

Editorial Board

Click here to see the editorial board members.

Focus and Scope

Cancer and Tumor Review is an international Open Access journal that publishes articles related to all areas of cancers and tumors. The topics of interest include but not limited to diagnosis, therapy, imaging, prevention, quality of life, supportive care, education and awareness.

For Authors

  • A manuscript would not be accepted if it has been published or is currently under consideration for publication in any other journals. The author will need to notify the editorial team if the data in their submission has been presented in conferences.

  • Authorship should be limited to people who have contributed substantially to the work. Authors must indicate their specific contributions to the published work. This information should be listed in the manuscript under the section ‘Author Contribution’. Examples of contributions include: designed research, performed research, contributed new reagents or analytic tools, analyzed data, wrote the paper.

    For more information on submission’s format, please refer to the ‘Author Guidelines’ link accessible from the ‘About’ button at the top row of this page.

    The corresponding author should be clearly indicated for all manuscripts submitted. A maximum of two corresponding authors are allowed for the responsibilities associated. The corresponding author(s) is responsible for:

    • Obtaining permission from all the authors mentioned in the manuscript
    • Ensuring adherence to all editorial and submission policies and for any communications and actions that may be necessary after publication
    • Including written permission from the authors of the work concerned for any mention of any unpublished material included in the manuscript, e.g. data from manuscripts-in-press, personal communication, or work in preparation.
  • The author has to provide the authorization of no conflict with any financial body or funding agency that might influence the results or interpretation of their manuscript. All authors, members, reviewers and editors must disclose any association that poses a conflict of interest in connection with the manuscript. The corresponding author will be asked to sign a form behalf of all of the authors regarding potential conflicts of interest at the time of acceptance.

  • The editorial team does not approve of any plagiarism attempts. iThenticate will be utilized at the editor’s discretion to verify the originality of submitted manuscripts. If plagiarism is detected during the review process the manuscript may be rejected pending the severity of plagiarism. Therefore, if a manuscript uses a text copied directly from another source, this text must be written in quotation marks and the original source must be cited.

  • All articles must be written in English — preferably American English. SI units should be used. If you are not a native English speaker, you may want to utilize an external or Whioce Publishing’s optional professional language editing service before submitting the final version.

  • Whioce Publishing Pte Ltd offers its own professional editing services. By using this service, you can be sure that your English-language manuscript will be polished and ready for submission to your publication of choice at a very reasonable price. For further details about the Language Editing Services, please contact us at Please note that utilizing a language editing service is not a guarantee of acceptance.

  • Revised manuscripts must contain a detailed point by point response to the comments of the reviewers. The response to reviewers has to be uploaded as a separate file.

  • If you withdraw your manuscript after it has been accepted (but not yet published), you will be charged for costs incurred at USD200.

  • Authors are expected to have minimum amount of post-acquisition processing of data. In case of processing; alterations must be applied to the entire image (e.g., brightness, contrast, color balance). Any kind of alteration if being done has to be clearly stated in the figure legend and in Methods section.

    Grouping of data (e.g., cropping of images of removal of lanes from gels and bolts) must be made apparent and should be explicitly indicated in the appropriate figure legends. Data comparisons should only be made from comparative experiments, and individual data should not be utilized across multiple figures. If inappropriate image/data manipulation is identified after publication, we reserve the right to ask for the original data and, if that is not satisfactory, to issue a correction or retract the paper, as appropriate.

  • Whioce Publishing will preserve e-journals with Portico, ensuring that they will be secure and available into the future.

  • The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

Article Processing Charges (APC)

Cancer and Tumor Review is an Open Access Journal under Whioce Publishing. All articles published in Cancer and Tumor Review are accessible electronically from the journal website without commencing any kind of payment. In order to ensure contents are freely available and maintain publishing quality, Article Process Charges (APC) is applicable to all authors who wish to submit their articles to the journal to cover the cost incurred in processing the manuscripts. Such cost will cover the peer-review, copyediting, typesetting, publishing, content depositing and archiving processes. Those charges are applicable only to authors who have their manuscript successfully accepted after peer-review.

Journal TitleAPC
Cancer and Tumor Review$800

We encourage authors to publish their papers with us and don’t wish the cost of article processing fees to be a barrier especially to authors from the low and lower middle income countries/regions. A range of discounts or waivers are offered to authors who are unable to pay our publication processing fees. Authors can write in to apply for a waiver and requests will be considered on a case-by-case basis.

Authors based in these countries/regions listed below may apply to receive up to a 50%-100% waiver of the standard article processing fee; Waiver subjected to approval.

  • Afghanistan
  • Armenia
  • Bangladesh
  • Benin
  • Bhutan
  • Bolivia
  • Burkina Faso
  • Burundi
  • Cabo Verde
  • Cambodia
  • Cameroon
  • Central African Republic
  • Chad
  • Comoros
  • Congo, Dem. Rep
  • Congo, Rep.
  • Côte d'Ivoire
  • Djibouti
  • Egypt, Arab Rep.
  • El Salvador
  • Eritrea
  • Ethiopia
  • Gambia, The
  • Ghana
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Haiti
  • Honduras
  • India
  • Indonesia
  • Kenya
  • Kiribati
  • Korea, Dem. People's Rep.
  • Kosovo
  • Kyrgyz Republic
  • Lao PDR
  • Lesotho
  • Liberia
  • Madagascar
  • Malawi
  • Mali
  • Mauritania
  • Micronesia, Fed. Sts.
  • Moldova
  • Mongolia
  • Morocco
  • Mozambique
  • Myanmar
  • Nepal
  • Nicaragua
  • Niger
  • Nigeria
  • Pakistan
  • Papua New Guinea
  • Philippines
  • Rwanda
  • Samoa
  • São Tomé and Principe
  • Senegal
  • Sierra Leone
  • Solomon Islands
  • Somalia
  • South Sudan
  • Sri Lanka
  • Sudan
  • Swaziland
  • Syrian Arab Republic
  • Tajikistan
  • Tanzania
  • Timor-Leste
  • Togo
  • Tonga
  • Tunisia
  • Uganda
  • Ukraine
  • Uzbekistan
  • Vanuatu
  • Vietnam
  • West Bank and Gaza
  • Yemen, Rep.
  • Zambia
  • Zimbabwe

If you are residing in one of the above mentioned countries and need to apply for a waiver, please email our editorial department ( with the following information:

  • Your name and institution with full address details
  • Title of journal you wish to submit a manuscript to
  • Reason for applying for a waiver
  • Title of your paper
  • Country of residence of all co-author

APC Payment

Payments for APC of this journal can be made through our online PayPal payment gateway. Enter the article no. into the below textbox and select "Pay Now" to proceed with payment.

Article No.

*Article No. is mandatory for payment and it can be found on the acceptance letter issued by the Editorial Office. Payment without indicating Article No. will result in processing problem and delay in article processing. Please note that payments will be processed in USD. You can make payment through Masters, Visa or UnionPay card.

Frequently Asked Questions

  • Answer: To establish whether your paper is suitable for this journal, please read Focus and Scope under Editorial Policies.
  • Answer: Registration and login are required to submit manuscript online and to check the status of current submission.
  • Answer: The submission file can be submitted in OpenOffice, Microsoft Word, RTF, or WordPerfect document file format.
  • Answer: The length of the manuscript cannot be more than 8000 words.
  • Answer: The cover letter is necessary for each submission. The cover letter should be uploaded as a separate file in Step 4 during the submission. The contents of the cover letter should include brief explanation of what was previously known, the conceptual advancement with the findings and its significance to broad readership. The cover letter will only be visible to the editor. Reviewers will not have access to the cover letter.
  • Answer: You can suggest 2 reviewers for your submission. However, the decision of whether to invite them lies with the Editor.
  • Answer: This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Refer to the Publication Fees tab for more details.